Abstract
The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.
| Original language | English |
|---|---|
| Pages (from-to) | 186-195 |
| Number of pages | 10 |
| Journal | Alzheimer's and Dementia |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Feb 2017 |
Cite this
}
Recommended cognitive outcomes in preclinical Alzheimer's disease : Consensus statement from the European Prevention of Alzheimer's Dementia project. / Ritchie, Karen; Ropacki, Michael; Albala, Bruce; Harrison, John; Kaye, Jeffrey; Kramer, Joel; Randolph, Christopher; Ritchie, Craig W.
In: Alzheimer's and Dementia, Vol. 13, No. 2, 01.02.2017, p. 186-195.Research output: Contribution to journal › Short survey › Academic › peer-review
TY - JOUR
T1 - Recommended cognitive outcomes in preclinical Alzheimer's disease
T2 - Consensus statement from the European Prevention of Alzheimer's Dementia project
AU - Ritchie, Karen
AU - Ropacki, Michael
AU - Albala, Bruce
AU - Harrison, John
AU - Kaye, Jeffrey
AU - Kramer, Joel
AU - Randolph, Christopher
AU - Ritchie, Craig W.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.
AB - The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.
KW - Alzheimer's disease
KW - Cognition
KW - Neuropsychology
KW - Preclinical
UR - http://www.scopus.com/inward/record.url?scp=85006295188&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2016.07.154
DO - 10.1016/j.jalz.2016.07.154
M3 - Short survey
VL - 13
SP - 186
EP - 195
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
SN - 1552-5260
IS - 2
ER -